With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...

In conclusion, GlaxoSmithKline's shares showed significant gains today, reflecting positive market sentiment and strong ...

How GlaxoSmithKline missed red flags in China By Ben Hirschler July 19, 20136:40 AM PDTUpdated July 19, 2013 ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, leading to its shares declining the most in nearly four months.

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs for its inhalers at $35 a month, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow through ...

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday (Apr 25), accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies’ ...

GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) reported an 18% revenue growth, with all business segments achieving double-digit growth. The company maintained strong volume growth in both ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies ...

July 14, 2010 -- In the face of mounting evidence that GlaxoSmithKline withheld important safety data on their controversial drug Avandia, some doctors are abandoning use of this diabetes treatment.